Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14347573 | 0.85 | PDGFRB (0.38) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL15985062 | 0.82 | ALDH1A1 (0.44) | MEN1KMT2AARPGRCYP3A4 | |
| SCHEMBL16110049 | 0.81 | PDGFRB (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1967675 | 0.80 | ABL1 (0.48) | NOTUMMEN1KMT2AVCAM1ALDH1A1 | |
| SCHEMBL28549978 | 0.80 | AR (0.38) | MEN1KMT2AARPGRCYP3A4 | |
| SCHEMBL306012 | 0.80 | MEN1 (0.46) | PKMMEN1KMT2ACYP2C9ALDH1A1 | |
| SCHEMBL28358908 | 0.79 | GAA (0.36) | ABCB1ABCC1MEN1KMT2AAR | |
| SCHEMBL31248747 | 0.79 | AR (0.38) | PKMMEN1KMT2AARPGR | |
| SCHEMBL17042263 | 0.78 | SOS1 (0.36) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL14249660 | 0.78 | PDGFRB (0.43) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8481544-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8426426-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426426-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-8389516-B2 | Antibacterial compositions | BIOTA EUROPE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2034997-B1 | ANTIBACTERIAL COMPOSITIONS | BIOTA EUROPE LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004221-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20110263590-A1 | Antibacterial Compositions | BIOTA EUROPE LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-05 | — | — | US | disclosed |
| US-7727992-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727992-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-29 | — | — | US | disclosed |
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-29 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| EP-2034997-A1 | ANTIBACTERIAL COMPOSITIONS | Prolysis Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007148093-A1 | ANTIBACTERIAL COMPOSITIONS | PROLYSIS LTD. (GB) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004221-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | PDGFRB 2748/4885FGFR1 1696/4885PDGFRA 2923/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | PDGFRB 3566/4885FGFR1 3122/4885PDGFRA 4053/4885 |
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | GMPS, NQO2, TOP1 | PDGFRB 4443/4885FGFR1 4319/4885PDGFRA 4521/4885 |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | GMPS, NQO2, TOP1 | PDGFRB 4443/4885FGFR1 4319/4885PDGFRA 4521/4885 |
| US-20110263590-A1 | Antibacterial Compositions | CYCS, COX6C, RPS6 | PDGFRB 2802/4885FGFR1 1572/4885PDGFRA 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.